Magnum Compounding LLC
490 W 84 St, Hialeah, FL 33014
Phone: (786) 622-2301
Fax: (786) 622-2319
Toll Free: (855) 403-6028

COMPOUNDED INJECTABLE FORMULA INFORMATION SHEET

ONLY WITH MEDICAL JUSTIFICATION

Product Name: Semaglutide

Formulation Type: Sterile Injectable Solution (Subcutaneous Use Only)

Vial Size: 2 mL Multi-Dose Vial (MDV)

ACTIVE INGREDIENTS (per mL)

Ingredients	Strength (mg / mL)	Role & Benefits
Semaglutide	1.2 mg, 2.4 mg, 4.8 mg, 10 mg	GLP-1 receptor agonist for glycemic control and appetite suppression.
Niacinamide	6 mg	Supports insulin sensitivity and reduces inflammation.
L-Carnitine	50 mg	Assists in fatty acid metabolism and energy production.

OTHER INGREDIENTS:

- Benzyl Alcohol 0.9% (Preservative)
- Water for Injection, USP (Vehicle)
- pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid

DESCRIPTION: This compounded formulation combines Semaglutide, a GLP-1 receptor agonist, with Niacinamide and L-Carnitine to support glucose regulation, enhance fat metabolism, and promote metabolic health. It is intended for subcutaneous administration and may be used as part of a comprehensive weight management or metabolic wellness program.

INDICATIONS:

- Support for weight management and metabolic health
- Adjunct to diet and exercise for glucose regulation
- Fatty acid metabolism and energy enhancement

DOSAGE & ADMINISTRATION:

- Route: Subcutaneous injection (SC) only
- Typical Dosage: As directed by a licensed healthcare provider
- Administer in the abdomen or thigh using proper aseptic technique

*This product is to be administered under licensed medical supervision.

If you have any questions or concerns regarding your medication, please do not hesitate to contact us.

Magnum Compounding LLC
490 W 84 St, Hialeah, FL 33014
Phone: (786) 622-2301
Fax: (786) 622-2319
Toll Free: (855) 403-6028

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light and heat. Do not freeze.

WARNINGS & PRECAUTIONS:

- Do not use in patients with a personal or family history of medullary thyroid carcinoma
- Not for use in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Use caution in patients with renal or hepatic impairment
- Monitor for signs of pancreatitis or hypoglycemia when used with insulin or sulfonylureas

POTENTIAL SIDE EFFECTS:

- Localized pain at the injection site
- Mild flushing, tingling, or dizziness
- Rare: allergic reaction or anaphylaxis
- Notify the provider of any unusual or persistent symptoms

DRUG DISPOSAL: Unused or expired compounded medications should be disposed of properly according to local regulations. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Consult with your pharmacy or local waste disposal authority for appropriate disposal methods. Magnum Compounding LLC can provide guidance or accept returned compounds for proper disposal when applicable.

SHIPPING & HANDLING: Shipped cold. Do not use it if exposed to improper temperature or physical damage. Inspect before use.

INJECTION SAFETY CONSIDERATIONS (CDC GUIDANCE):

- Medications should be drawn up in a designated clean medication preparation area using a new sterile syringe and sterile needle.
- Prepare an injection as close as possible to the time of administration to the patient.
- Do NOT leave the needle inserted into a medication vial septum for multiple uses.
- Vials labeled as single-dose or single-use should be used for only a single patient and entered only once.
- Do NOT combine (pool) leftover contents of single-dose or single-use vials or store them for later use.
- If a single-dose or single-use vial has been opened or accessed (e.g., needle-punctured), it should be discarded according to pharmacy policy or at the end of the procedure, whichever is sooner.
- Discard any medication vial if sterility is compromised or questionable.
- Multi-dose vials should be dedicated to a single patient whenever possible.
- Once opened, multi-dose vials must be dated and discarded within 28 days unless otherwise specified by the pharmacy label.

VISION CHANGES WARNING

See page 3 for the FDA NAION safety update and urgent vision symptoms.

If you have any questions or concerns regarding your medication, please do not hesitate to contact us.

Magnum Compounding LLC
490 W 84 St, Hialeah, FL 33014
Phone: (786) 622-2301
Fax: (786) 622-2319
Toll Free: (855) 403-6028

VISION CHANGES WARNING

FDA SAFETY UPDATE - NOVEMBER 9, 2026

FDA warns of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) with GLP-1 receptor agonists, including semaglutide. This rare optic nerve condition can cause sudden, painless loss of vision in one eye, which may be permanent.

WHEN TO SEEK IMMEDIATE MEDICAL ATTENTION

Seek immediate medical attention for sudden decreased or lost vision, missing areas of vision, blind spots, tunnel vision, or new color distortion. Contact your prescriber immediately; suspected NAION requires prompt ophthalmologist evaluation.

INFORMATION FOR THE PRESCRIBING CLINICIAN

Consider discontinuing the GLP-1 medication if NAION develops unless treatment benefits clearly outweigh the risk. Patients with previous NAION should discuss treatment risks and benefits with their clinician. Report suspected adverse events to FDA MedWatch.

DIABETIC RETINOPATHY AND MONITORING

Rapid improvement in blood glucose control may temporarily worsen diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored by their healthcare provider. Report new or persistent visual changes and maintain recommended eye examinations. NAION affects the optic nerve and is distinct from diabetic retinopathy.

MEDICAL DISCLAIMER

Clinical evaluation, monitoring, and treatment decisions should be determined by the prescribing healthcare provider. This compounded preparation is not FDA-approved. The FDA labeling action applies to approved GLP-1 products; this safety information is included here to support patient counseling.

REFERENCES

1. FDA Drug Safety Communication, November 9, 2026: GLP-1 receptor agonists and potential NAION risk.

2. Semaglutide FDA prescribing information (diabetic retinopathy precautions).
3. Niacinamide in Metabolic Health - NIH Database.
4. L-Carnitine Pharmacological Profile - PubMed/NCBI.

Vision safety section updated November 10, 2026.

If you have any questions or concerns regarding your medication, please do not hesitate to contact us.